Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul Frankel"'
Autor:
Erasmus Poku, David Colcher, James R. Bading, Mary Caroll, Paul Frankel, Joanne E. Mortimer, Jinha M. Park, Yuan Yuan, John E. Shively, Lusine Tumyan, Nikita Gidwaney
Publikováno v:
J Nucl Med
Trastuzumab emtansine (T-DM1) is an antibody drug conjugate used to treat HER2-positive breast cancer. We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict patient response to T-DM1 therapy. Methods: Ten women with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f67fff2bdbaac4637c9bcae3d9338f1
https://europepmc.org/articles/PMC9364339/
https://europepmc.org/articles/PMC9364339/
Autor:
Erasmus Poku, David Colcher, James R. Bading, Paul Frankel, Jinha M. Park, Russell C. Rockne, Andrew Raubitschek, Tri Tran, John E. Shively, Joanne E. Mortimer, Mary Carroll
Publikováno v:
Journal of Nuclear Medicine. 59:38-43
The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2
Autor:
Paul Frankel, Erasmus Poku, Joanne E. Mortimer, David Colcher, James R. Bading, Mary Carroll, John E. Shively, Andrew Raubitschek, Joshua K. Miles, Shan Tong, Peter S. Conti
Publikováno v:
Journal of Nuclear Medicine. 55:23-29
Women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 status in recurrent disease is usually made by core needle biopsy of a single